Carisma Therapeutics (CARM) Earnings Date, Estimates & Call Transcripts → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free CARM Stock Alerts $1.08 -0.03 (-2.70%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 8EstimatedActual EPS (May. 9) -$0.46 Missed By -$0.09 Consensus EPS (May. 9) -$0.37 Get Carisma Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CARM and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCARM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CARM Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Oasis GoldExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! Carisma Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.47)($0.26)($0.37)Q2 20242($0.45)($0.27)($0.36)Q3 20242($0.43)($0.29)($0.36)Q4 20242($0.47)($0.26)($0.37)FY 20248($1.82)($1.08)($1.45)Q1 20251($0.48)($0.48)($0.48)Q2 20251($0.50)($0.50)($0.50)Q3 20251($0.54)($0.54)($0.54)Q4 20251($0.56)($0.56)($0.56)FY 20254($2.08)($2.08)($2.08)CARM Earnings Date and InformationCarisma Therapeutics last announced its earnings results on May 9th, 2024. The reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.09. The business had revenue of $3.40 million for the quarter, compared to analysts' expectations of $3.90 million. Carisma Therapeutics has generated ($2.00) earnings per share over the last year (($2.00) diluted earnings per share). Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.72) to ($1.53) per share. Carisma Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off prior year's report dates.Read More Carisma Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/8/2024(Estimated)------- 5/9/2024Q1 2024($0.37)($0.46)($0.09)($0.46)$3.90 million$3.40 million4/1/2024Q4 2023-($0.52)($0.52)($0.52)$4.00 million$4.29 million11/9/2023Q3 2023($0.60)($0.53)+$0.07($0.53)-$3.83 million8/10/2023Q2 2023($0.66)($0.49)+$0.17($0.49)-$3.56 million5/11/2023Q1 2023-($1.93)($1.93)($1.93)-$3.24 million2/28/2023Q4 2022($2.20)($0.80)+$1.40($0.80)-- Get the Latest News and Ratings for CARM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/7/2022Q3 2022($1.60)$2.80+$4.40$3.60-$0.04 million8/8/2022Q2 2022($2.60)($1.00)+$1.60$1.20--2/28/2022Q4 2021($1.60)$0.40+$2.00--$20.00 million11/8/2021Q3 2021($1.40)($0.40)+$1.00($8.00)--8/9/2021Q2 2021($1.20)($1.40)($0.20)$0.20$2.40 million$2.23 million5/10/2021Q1 2021($1.20)($7.00)($5.80)($7.00)-$4.31 million3/15/2021Q4 2020($2.00)($1.40)+$0.60($0.60)--11/9/2020Q3 2020($1.80)($3.80)($2.00)($3.80)-$11.24 million8/10/2020Q2 2020($1.80)($4.80)($3.00)($4.80)--5/11/2020Q1 2020($2.00)$6.20+$8.20$6.20--3/16/2020Q4 2019-($1.60)($1.60)$3.20--11/12/2019Q3 2019($1.60)($2.60)($1.00)($2.60)--8/8/2019Q2 2019($1.80)($2.60)($0.80)$8.20-- Carisma Therapeutics Earnings - Frequently Asked Questions When is Carisma Therapeutics's earnings date? Carisma Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates. Learn more on CARM's earnings history. Did Carisma Therapeutics beat their earnings estimates last quarter? In the previous quarter, Carisma Therapeutics (NASDAQ:CARM) missed the analysts' consensus estimate of ($0.37) by $0.09 with a reported earnings per share (EPS) of ($0.46). Learn more on analysts' earnings estimate vs. CARM's actual earnings. How much revenue does Carisma Therapeutics generate each year? Carisma Therapeutics (NASDAQ:CARM) has a recorded annual revenue of $14.92 million. How much profit does Carisma Therapeutics generate each year? Carisma Therapeutics (NASDAQ:CARM) has a recorded net income of -$86.88 million. CARM has generated -$2.00 earnings per share over the last four quarters. What is Carisma Therapeutics's EPS forecast for next year? Carisma Therapeutics's earnings are expected to grow from ($1.72) per share to ($1.53) per share in the next year. More Earnings Resources from MarketBeat Related Companies: CTSO Earnings Results XGN Earnings Results AWH Earnings Results LFVN Earnings Results ADVM Earnings Results XBIT Earnings Results PYXS Earnings Results RENB Earnings Results OVID Earnings Results GBIO Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NASDAQ:CARM) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.